Emerging Psychiatric Treatments and Safe Medication Discontinuation — Chapter 22 Summary from Clinical Psychopharmacology for Therapists
Emerging Psychiatric Treatments and Safe Medication Discontinuation — Chapter 22 Summary from Clinical Psychopharmacology for Therapists Chapter 22 of Clinical Psychopharmacology for Therapists explores two critical themes in modern psychiatric care: the rise of emerging treatments such as ketamine and psychedelics, and the often-overlooked process of safely discontinuing psychotropic medications . With mental health care evolving rapidly, this chapter provides both hope and caution—highlighting new possibilities for treatment-resistant conditions and the importance of tapering medications to avoid serious withdrawal effects. 🎥 Watch the full video breakdown below for a podcast-style summary of this insightful chapter: Ketamine and the NMDA Receptor Revolution Originally developed as an anesthetic, ketamine is now at the forefront of research into treatment-resistant depression . It functions as an NMDA receptor antagonist , targeting the glutamate system rather than sero...